Signase: Src revival

The current popularity of kinases seems to have vindicated Andy Warhol's dictum that just about everyone gets to enjoy 15 minutes of fame. Almost every new addition to the kinase superfamily is touted as the target that will create the next blockbuster anti-cancer drug. Though focused on cancer, Signase Inc. is bucking this trend by refusing to focus on the latest kinases. Instead, the company

Read the full 658 word article

How to gain access

Continue reading with a
two-week free trial.